Fig. 1

rAAV6-CMV-A20 inhibits inflammation in CIA mice. a Immunofluorescence staining of A20 in joints that were injected with rAAV6-CMV-A20 (white arrow: synovium). b Clinical arthritis score of hind paws injected with rAAV6-CMV-EGFP or rAAV6-CMV-A20 (n = 15); Statistical analyses were performed between hind paws injected with rAAV6-CMV-EGFP and rAAV6-CMV-A20 using paired t-tests. c Hind paws of CIA mice injected with rAAV6-CMV-EGFP (right) or rAAV6-CMV-A20 (left) on the day 42nd after primary immunization. d Micro-CT 3D reconstruction image of hind paws. e HE or Safranin-O staining of joint specimens injected with rAAV6-CMV-EGFP or rAAV6-CMV-A20. f Hind paws of CIA mice injected with rAAV6-SP146-EGFP (right) or rAAV6-SP146-A20 (left) on the day 42nd after primary immunization. g Clinical arthritis score of hind paws injected with rAAV6-SP146-EGFP or rAAV6-SP146-A20 (n = 9); Statistical analyses were performed between hind paws injected with rAAV6-SP146-EGFP and rAAV6-SP146-A20 using paired t-tests. HE (h) and Safranin-O (i) staining of joint specimens injected with rAAV6-SP146-EGFP or rAAV6-SP146-A20. j Fluorescence image of RAW264.7 cells transfected with rAAV6-SP146-EGFP. k Western blotting of A20 in RAW264.7 cell lysates following transfection with rAAV6-CMV-A20 or rAAV6-SP146-A20. l Immunofluorescence staining of A20 and F4/80 in joint specimens injected with rAAV6-SP146-A20. CMV cytomegalovirus, NLRP3 NOD-like receptor protein 3